Experienced in Lymphadenectomy

Dr. Kimberly L. Levinson

Gynecologic Oncology | Oncology
Johns Hopkins University
600 N Wolf St, 
Baltimore, MD 
Accepting New Patients
Offers Telehealth
Experienced in Lymphadenectomy
Johns Hopkins University
600 N Wolf St, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kimberly Levinson is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Levinson is rated as an Experienced provider by MediFind in Lymphadenectomy. Her top areas of expertise are Endometrial Cancer, Testicular Yolk Sac Tumor, Ovarian Cancer, Hysterectomy, and Lymphadenectomy. Dr. Levinson is currently accepting new patients.

Her clinical research consists of co-authoring 64 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Lymphadenectomy.

Specialties
Gynecologic Oncology
Oncology
Licenses
Obstetrics & Gynecology in MD
Hospital Affiliations
Greater Baltimore Medical Center
The Johns Hopkins Hospital
Languages Spoken
English
American Sign Language
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

JOHNS HOPKINS UNIVERSITY
600 N Wolf St, Baltimore, MD 21287
Other Locations
GREATER BALTIMORE MEDICAL CENTER INC
6569 N Charles St, 307 Gyn Fertility Gbmc, Baltimore, MD 21204

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel
Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Carboplatin, Paclitaxel
Study Phase: Phase 3
A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus
A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus
Enrollment Status: Completed
Publish Date: November 16, 2021
Intervention Type: Procedure, Drug, Other
Study Phase: Early Phase 1
A Phase I Study of Intravaginally Administered Artesunate In Women With High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
A Phase I Study of Intravaginally Administered Artesunate In Women With High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
Enrollment Status: Completed
Publish Date: April 28, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

64 Total Publications

Barriers and Facilitators to Cancer Clinical Trial Participation: Perspectives of Patients in the ICON-3 Practice-Based Research Network, Nigeria.
Barriers and Facilitators to Cancer Clinical Trial Participation: Perspectives of Patients in the ICON-3 Practice-Based Research Network, Nigeria.
Journal: JCO global oncology
Published: October 08, 2025
Similar Doctors
Advanced in Lymphadenectomy
Dr. Lori Cory
Oncology
Advanced in Lymphadenectomy
Dr. Lori Cory
Oncology

Lancaster General Medical Group

2102 Harrisburg Pike, 
Lancaster, PA 
 (54.7 miles away)
717-544-9400
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lori Cory is an Oncologist in Lancaster, Pennsylvania. Dr. Cory is rated as a Distinguished provider by MediFind in Lymphadenectomy. Her top areas of expertise are Endometrial Cancer, Cervical Cancer, Malignant Mixed Mullerian Tumor, Lymphadenectomy, and Salpingo-Oophorectomy. Dr. Cory is currently accepting new patients.

Experienced in Lymphadenectomy
Dr. James S. Ferriss
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Experienced in Lymphadenectomy
Dr. James S. Ferriss
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (0.1 miles away)
410-955-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Ferriss is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Ferriss is rated as a Distinguished provider by MediFind in Lymphadenectomy. His top areas of expertise are Ovarian Cancer, Malignant Mixed Mullerian Tumor, Neuroendocrine Carcinoma of the Cervix, Oophorectomy, and Lymphadenectomy. Dr. Ferriss is currently accepting new patients.

Experienced in Lymphadenectomy
Dr. Stephanie L. Wethington
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Experienced in Lymphadenectomy
Dr. Stephanie L. Wethington
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
600 North Wolfe Street, Phipps 281, 
Baltimore, MD 
 (0.1 miles away)
410-955-8240
Languages Spoken:
English
See accepted insurances

Stephanie Wethington is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Wethington is rated as a Distinguished provider by MediFind in Lymphadenectomy. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Oophorectomy, and Hysterectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Levinson's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile